HOME >> MEDICINE >> NEWS
ARICEPT significantly improves cognition, daily living over Reminyl in Alzheimers patients

GENEVA, SWITZERLAND (4 APRIL 2002) - Results from the first head-to-head study comparing ARICEPT (donepezil HCl tablets) and Reminyl (galantamine HBr tablets) demonstrated significantly greater improvements in cognition and activities of daily living (ADLs) in mild to moderate Alzheimer's disease (AD) patients treated with ARICEPT vs. Reminyl. ARICEPT-treated patients showed significant benefit over patients receiving Reminyl as measured by the modified 13-item Alzheimer's Disease Assessment Scale-cognitive subscale (modified ADAS-cog), achieved significant improvements on the Mini-Mental State Examination (MMSE), and had significantly greater improvements in ADLs, as measured by the Disability Assessment for Dementia (DAD) scale total score. The study was primarily designed to evaluate safety and tolerability. The first-ever presentation of these data took place at the 7th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy (AAT) in Geneva, Switzerland.

"By comparing two available Alzheimer's disease medications, physicians now have clinical evidence that will help them prescribe the most appropriate treatment for their patients," said study investigator Roy Jones, MD, Research Institute for the Care of the Elderly, St Martin's Hospital, Bath, United Kingdom. "This three month study is encouraging news for mild to moderate Alzheimer's disease patients currently on ARICEPT, as well as those who have yet to initiate treatment." The 12-week, multinational (United Kingdom, Finland, Norway and Germany), head-to-head, randomized open-label study was designed primarily to evaluate the safety and tolerability of ARICEPT (n= 64) and Reminyl (n= 56) in 120 patients with possible or probable mild to moderate Alzheimer's disease. The study also investigated the effects of both treatments on cognition and ADLs, such as meal preparation and finance and correspondence. Trained raters who were blinded to study medication and trial results admin
'"/>


4-Apr-2002


Page: 1 2 3 4

Related medicine news :

1. First-of-its-kind study of vascular dementia patients taking ARICEPT presented at AAGP meeting
2. Vascular dementia patients taking ARICEPT show significant treatment benefits in cognition and function
3. ARICEPT better tolerated than Exelon in patients with mild to moderate Alzheimers disease
4. Moving admitted ER patients into inpatient beds faster could significantly increase hospital revenue
5. Gastrointestinal disorders are associated significantly with sleepless nights
6. Landmark survey reveals asthma in children remains significantly out of control in the United States
7. Data suggest ADDERALL XR significantly improved simulated driving in young adults with ADHD
8. Elderly cancer patients are significantly under-represented in cancer clinical trials
9. Generic anti-inflammatory causes significantly fewer GI complications than branded medications
10. Study shows weight-based REBETOL dosing in combination with PEG-INTRON significantly improves ...
11. Radiotherapy + cetuximab significantly improve disease control and survival in head and neck cancer

Post Your Comments:
(Date:2/28/2015)... TX (PRWEB) March 01, 2015 Heart ... estimated that 10 percent of urban adult population and ... form of heart diseases and 20-30 percent of them ... to heart ailments and coronary vascular diseases (CVD). , ... launched a new market research report titled “Indian Coronary ...
(Date:2/28/2015)... Gerald “Solutionman” Haman surveyed over 10,000 people to ... thinking. “The #1 block was lack of time ... Haman, who created the Thinkubator Innovation Studio in Chicago. ... they did not have enough time for innovative thinking ... innovation. , Solutionman’s monthly “Accelerating Innovation Training” workshops address ...
(Date:2/28/2015)... The Heart Fit Clinic started doing External Counterpulsation ... The Heart Fit Clinic is also selling the machines ... The goal is to scale the business to help ... buy External Counterpulsation machines can be difficult process. ... process and achieve the desired results. , The ...
(Date:2/28/2015)... NJ (PRWEB) February 28, 2015 ... a good time to remind ourselves and others ... ignored, say Atlantic NeuroSurgical Specialists (ANS). , Concussions ... which account for 75% of TBIs. There are ... concussion may sound benign, but it is a ...
(Date:2/28/2015)... Vancouver personal injury lawyers at Jiwa Law Corporation ... time limits. They stated that in many cases, missing an ... nullify it. Many a time, delays in making an injury ... BC law. As a result, experts at Jiwa Law Corporation ... a personal injury lawyer in order to know more about ...
Breaking Medicine News(10 mins):Health News:India Coronary Stent Market 2019 Forecasts Analysis in New Research Report Available at MarketReportsOnline.com 2Health News:India Coronary Stent Market 2019 Forecasts Analysis in New Research Report Available at MarketReportsOnline.com 3Health News:New Survey Reveals “Lack of Time” Is the Number #1 Barrier to Innovative Thinking 2Health News:New Survey Reveals “Lack of Time” Is the Number #1 Barrier to Innovative Thinking 3Health News:Clinicians Can Now Purchase External Counterpulsation with Heart Fit Clinic 2Health News:Atlantic NeuroSurgical Specialists (ANS) Focus on National Brain Injury Awareness Month to Educate the General Public on Head Trauma 2Health News:Atlantic NeuroSurgical Specialists (ANS) Focus on National Brain Injury Awareness Month to Educate the General Public on Head Trauma 3Health News:Jiwa Law Corporation Recently Announced That Time Delays May Weaken Personal Injury Claims 2
(Date:3/1/2015)... WASHINGTON , March 1, 2015  USPlabs ... of the following and states that media reports ... false: On Saturday, February 28, 2015, ... issued a Public Notification on the contamination of ... Super Thermogenic (referred to below as "OEP") with ...
(Date:2/27/2015)... , Feb. 27, 2015 WuXi PharmaTech ... and technology platform company serving the pharmaceutical, biotechnology, and ... and the United States ... therapy designation from the U.S. FDA for ibalizumab (TMB355). ... if it is intended, alone or in combination with ...
(Date:2/27/2015)... , Feb. 27, 2015  Following a bipartisan ... that moved H.R. 284, the Medicare DMEPOS Competitive ... Association for Homecare (AAHomecare) released a statement praising ... to pass the legislation. "Today,s mark-up ... House Ways and Means Committee is a critical ...
Breaking Medicine Technology:OEP Product Is Counterfeit 2WuXi Congratulates TaiMed Biologics on Receiving Breakthrough Therapy Designation from U.S. FDA 2Bidding Fix Takes Major Step Forward After Bipartisan Vote of House Ways and Means Committee 2
Cached News: